Cogent Biosciences printed its Q2 results on August 13 into a stock already down nearly 10% on the week — and the data since has shifted meaningfully from the bullish setup described in notes filed earlier this week.
The most important change is in short interest, which has moved in the wrong direction for longs. SI jumped 13% in a single session on August 11 to 11.4% of the free float — roughly 17.4 million shares — the highest reading in over a month and up nearly 20% versus 30 days ago. That reverses the modest short covering described in the previous notes and puts the short base back near levels last seen in mid-July. Cost to borrow remains low at 0.57%, barely changed on the week, which means new shorts are paying almost nothing to press the position. Availability is loose at 801% — more than eight shares available to borrow for every one currently lent out — so there is no mechanical constraint on further short building. The ORTEX short score has climbed to 58.2, its highest reading in the past two weeks, consistent with the rebuilding trend.
Options positioning has also shifted, though the move is less dramatic than the short interest spike. The put/call ratio hit 0.2076 on August 11 — the 52-week low, and now more than two standard deviations below its 20-day average of 0.267. On the surface that still reads as call-heavy. But the direction of travel matters: the PCR was 0.31 on August 4 and has compressed sharply as the stock sold off, which likely reflects put decay and expiring hedges rather than fresh bullish call buying. The 52-week high on the PCR is 1.08 — so the current reading sits at one extreme of a very wide band, and the gap between options optimism and short interest rebuilding is the central tension in this name right now.
The Street remains constructive despite the price action. Guggenheim raised its target to $52 from $45 this morning — the most recent analyst action and a notable move given the stock closed at $38.70. The broader analyst community is aligned bullish, with targets clustered in the $52–$55 range and a mean of $53.83, implying roughly 39% upside from current levels. The bull case rests on bezuclastinib's November 30 PDUFA date for GIST and its potential in systemic mastocytosis — two indications where the drug targets the underlying biology rather than symptoms. The bear case is the one playing out in the stock price: binary regulatory risk, deep negative earnings (EV/EBITDA of -20.3x), and a price-to-book of 19.2x that leaves little margin for a clinical disappointment. The EPS surprise factor score of 57 is middling, and the short score rank of 30 suggests ORTEX's composite model is not flagging an extreme setup — just an elevated one.
Institutional ownership offers some context on who is holding through the weakness. FMR (Fidelity) is the largest holder at 13.5% of shares, followed by BlackRock at 10.2%. Both added shares in the period ending July 31 — BlackRock by over 1.3 million shares. Janus Henderson also added 1.4 million shares over the same period. That institutional accumulation at current price levels is a meaningful counterweight to the short rebuilding. Fairmount Funds, which sold 7 million shares in March at $34.66, has been the most visible seller — though that data is now stale at 134 days old.
Earnings history adds a final layer. The last three prints produced next-day moves of -8.7%, +0.7%, and -5.9% respectively. The pattern is asymmetric to the downside on the day itself, though the June print recovered to +6.1% over five days. With the stock now at $38.70 and the quarterly numbers largely irrelevant to the thesis, the August 13 print is less a financial event and more a management communication exercise — what matters is any update on the November PDUFA timeline, enrollment data, or commercial preparation commentary around bezuclastinib.
The next meaningful watch point is any post-earnings commentary on the PDUFA readiness timeline, which will either validate or challenge the call-heavy options positioning that has remained in place even as shorts have rebuilt sharply over the past two sessions.
See the live data behind this article on ORTEX.
Open COGT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
